Septerna, Inc. (NASDAQ:SEPN) Short Interest Update

Septerna, Inc. (NASDAQ:SEPN) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,941,013 shares, an increase of 36.0% from the December 31st total of 1,427,098 shares. Currently, 4.5% of the shares of the stock are sold short. Based on an average trading volume of 319,319 shares, the short-interest ratio is presently 6.1 days. Based on an average trading volume of 319,319 shares, the short-interest ratio is presently 6.1 days. Currently, 4.5% of the shares of the stock are sold short.

Insider Activity

In other news, SVP Daniel D. Long sold 3,501 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $18.06, for a total value of $63,228.06. Following the completion of the transaction, the senior vice president directly owned 92,911 shares in the company, valued at $1,677,972.66. This trade represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Septerna

Several institutional investors and hedge funds have recently modified their holdings of SEPN. Russell Investments Group Ltd. acquired a new stake in Septerna in the 3rd quarter worth approximately $36,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Septerna in the fourth quarter worth $61,000. Covestor Ltd lifted its stake in shares of Septerna by 55.8% in the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock worth $68,000 after buying an additional 1,296 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Septerna by 88.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock worth $78,000 after buying an additional 1,945 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after acquiring an additional 1,315 shares during the period.

Septerna Stock Performance

NASDAQ:SEPN traded down $0.46 during trading hours on Friday, hitting $23.34. 282,418 shares of the company’s stock traded hands, compared to its average volume of 275,700. The stock’s fifty day moving average price is $26.89 and its two-hundred day moving average price is $20.26. The firm has a market cap of $1.04 billion, a P/E ratio of -15.46 and a beta of 3.85. Septerna has a twelve month low of $4.17 and a twelve month high of $30.50.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.28). Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. The firm had revenue of $21.50 million for the quarter, compared to analyst estimates of $24.50 million. On average, equities research analysts predict that Septerna will post -7.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Zacks Research downgraded Septerna from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. HC Wainwright lifted their price target on Septerna from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Truist Financial started coverage on Septerna in a report on Monday, December 15th. They set a “buy” rating and a $34.00 price objective on the stock. Raymond James Financial initiated coverage on shares of Septerna in a report on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 target price for the company. Finally, Wells Fargo & Company upgraded shares of Septerna from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $18.00 to $28.00 in a report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $33.83.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.